Baidu
map

Nat Metab:“跨界神药”二甲双胍能减肥,原来和它有关!

2019-12-11 Walter 转化医学网

导 语:二甲双胍是世界上使用最广泛的药物之一,主要用于2型糖尿病治疗。除了降血糖的作用,研究逐渐证实二甲双胍在衰老、认知障碍、癌症和心血管疾病的治疗中扮演重要角色。二甲双胍“跨界神药”的地位日渐巩固,但其广泛作用的背后机制尚不为人知。

导 语:二甲双胍是世界上使用最广泛的药物之一,主要用于2型糖尿病治疗。除了降血糖的作用,研究逐渐证实二甲双胍在衰老、认知障碍、癌症和心血管疾病的治疗中扮演重要角色。二甲双胍“跨界神药”的地位日渐巩固,但其广泛作用的背后机制尚不为人知。

近日,加拿大麦克马斯特大学代谢中心的Gregory R. Steinberg课题组发现二甲双胍引起的食欲降低和体重减轻与生长分化因子15(GDF15)的转录和分泌增加有关。研究者解释了二甲双胍用作减肥药物的可能机制,并掀起揭示二甲双胍作用于其他相关疾病的临床实验热潮。这些结果12月9日发表在《Nature Metabolism》上。



二甲双胍降血糖的机制目前已得到解析,主要通过磷酸化APK激酶和抑制乙酰辅酶A来提高胰岛素敏感性,改变肠道微生物组并刺激胰高血糖样肽释放。研究表明,二甲双胍使2型糖尿病病人和正常人体重减轻,通过抑制食欲,减少热量摄入,而几乎不增加能量消耗,其背后机制尚不清楚。

二甲双胍在生理pH条件下以阳离子态存在,不能透过细胞膜。临床口服剂量(250-300 mg/ kg)下,二甲双胍在肝脏中富集浓度可达40-1000 M,而血浆浓度仅为10-15 M。因此,作者推测二甲双胍可能通过增加肝细胞内分泌因子的生成,促进与中枢神经系统的交互,从而产生减轻体重的作用。

首先,研究者对二甲双胍给药组小鼠原代肝细胞进行转录组学分析,发现55种分泌蛋白的基因表达较对照组改变。为了确定临床相关性,将以上蛋白与二甲双胍治疗的2型糖尿病病人血清中的蛋白进行比对,发现生长分化因子15(growth differentiating factor, GDF15)的上调最为显著。

GDF15是转化生长因子β(TGF-β)超家族的成员,在肝脏中高表达。最近的研究表明,重组GDF15与脑干中的GDNF受体相互作用,抑制食欲并促进体重减轻。在服用二甲双胍2型糖尿病患者中观察到血清中GDF15含量与体重减轻成正相关。


二甲双胍增加GDF15表达,并与2型糖尿病患者用药后体重下降有关

接着,研究者在小鼠原代肝细胞中进行体外给药实验。二甲双胍使GDF15的表达增加55%,结构相似的苯甲双胍和丁双胍也增加了肝细胞中GDF15的分泌。同时,作者证明二甲双胍引起GDF15释放与AMPK的激活无关,即与降血糖作用机制分别为两条通路。

此前有文献报道,GDF15的上游为应激调控的CHOP和ATF4。研究者使用siRNA对ATF4进行敲减后,二甲双胍处理引起肝细胞GDF15释放相对减少,说明二甲双胍通过调控ATF4和CHOP增加肝细胞GDF15的分泌。


二甲双胍调控应激通路增加肝细胞GDF15的分泌

进而,研究者发现在GDF15 基因敲除的小鼠中给予高脂饲料以及临床治疗剂量的二甲双胍,与相同处理的野生型小鼠相比,GDF-KO小鼠无法产生GDF15的上调,也不产生食欲降低和体重减轻的情况,证明GDF15蛋白对于二甲双胍减轻体重的必要性。


二甲双胍通过GFD15 减少高脂喂养小鼠的食物摄入

Gregory R. Steinberg等阐明二甲双胍通过上调肝细胞分泌的GDF15,从而抑制食欲并减轻体重,这是由ATF4应激通路介导的,而非二甲双胍降糖通路的继发作用。研究结果提示二甲双胍在肥胖人群中的潜在临床应用价值,为解析“神药”广泛的临床适用性提供重要借鉴!

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1896589, encodeId=b5961896589ea, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Dec 19 07:36:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797874, encodeId=370b1e97874c6, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu May 28 07:36:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888096, encodeId=e5b7188809662, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Dec 21 23:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884043, encodeId=0cc21884043a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 24 00:36:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376866, encodeId=13173e686665, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK83Truj8NUgr5VYUNTe7l5Etf3AUFceibcFt9t5vmbcM5jv0udUW2sQlPFF7movto7JJ7GXMKNh5A/132, createdBy=8f6b5243615, createdName=dong8372, createdTime=Thu Dec 12 13:43:26 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376839, encodeId=01cc3e683915, content=与长寿有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 11 19:36:34 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041500, encodeId=8a441041500b9, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048290, encodeId=103b104829031, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
    2019-12-19 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1896589, encodeId=b5961896589ea, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Dec 19 07:36:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797874, encodeId=370b1e97874c6, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu May 28 07:36:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888096, encodeId=e5b7188809662, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Dec 21 23:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884043, encodeId=0cc21884043a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 24 00:36:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376866, encodeId=13173e686665, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK83Truj8NUgr5VYUNTe7l5Etf3AUFceibcFt9t5vmbcM5jv0udUW2sQlPFF7movto7JJ7GXMKNh5A/132, createdBy=8f6b5243615, createdName=dong8372, createdTime=Thu Dec 12 13:43:26 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376839, encodeId=01cc3e683915, content=与长寿有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 11 19:36:34 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041500, encodeId=8a441041500b9, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048290, encodeId=103b104829031, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1896589, encodeId=b5961896589ea, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Dec 19 07:36:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797874, encodeId=370b1e97874c6, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu May 28 07:36:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888096, encodeId=e5b7188809662, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Dec 21 23:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884043, encodeId=0cc21884043a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 24 00:36:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376866, encodeId=13173e686665, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK83Truj8NUgr5VYUNTe7l5Etf3AUFceibcFt9t5vmbcM5jv0udUW2sQlPFF7movto7JJ7GXMKNh5A/132, createdBy=8f6b5243615, createdName=dong8372, createdTime=Thu Dec 12 13:43:26 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376839, encodeId=01cc3e683915, content=与长寿有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 11 19:36:34 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041500, encodeId=8a441041500b9, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048290, encodeId=103b104829031, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
    2019-12-21 guojianrong
  4. [GetPortalCommentsPageByObjectIdResponse(id=1896589, encodeId=b5961896589ea, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Dec 19 07:36:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797874, encodeId=370b1e97874c6, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu May 28 07:36:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888096, encodeId=e5b7188809662, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Dec 21 23:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884043, encodeId=0cc21884043a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 24 00:36:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376866, encodeId=13173e686665, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK83Truj8NUgr5VYUNTe7l5Etf3AUFceibcFt9t5vmbcM5jv0udUW2sQlPFF7movto7JJ7GXMKNh5A/132, createdBy=8f6b5243615, createdName=dong8372, createdTime=Thu Dec 12 13:43:26 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376839, encodeId=01cc3e683915, content=与长寿有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 11 19:36:34 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041500, encodeId=8a441041500b9, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048290, encodeId=103b104829031, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
    2020-05-24 liye789132251
  5. [GetPortalCommentsPageByObjectIdResponse(id=1896589, encodeId=b5961896589ea, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Dec 19 07:36:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797874, encodeId=370b1e97874c6, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu May 28 07:36:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888096, encodeId=e5b7188809662, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Dec 21 23:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884043, encodeId=0cc21884043a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 24 00:36:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376866, encodeId=13173e686665, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK83Truj8NUgr5VYUNTe7l5Etf3AUFceibcFt9t5vmbcM5jv0udUW2sQlPFF7movto7JJ7GXMKNh5A/132, createdBy=8f6b5243615, createdName=dong8372, createdTime=Thu Dec 12 13:43:26 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376839, encodeId=01cc3e683915, content=与长寿有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 11 19:36:34 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041500, encodeId=8a441041500b9, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048290, encodeId=103b104829031, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
    2019-12-12 dong8372

    很好

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1896589, encodeId=b5961896589ea, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Dec 19 07:36:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797874, encodeId=370b1e97874c6, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu May 28 07:36:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888096, encodeId=e5b7188809662, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Dec 21 23:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884043, encodeId=0cc21884043a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 24 00:36:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376866, encodeId=13173e686665, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK83Truj8NUgr5VYUNTe7l5Etf3AUFceibcFt9t5vmbcM5jv0udUW2sQlPFF7movto7JJ7GXMKNh5A/132, createdBy=8f6b5243615, createdName=dong8372, createdTime=Thu Dec 12 13:43:26 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376839, encodeId=01cc3e683915, content=与长寿有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 11 19:36:34 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041500, encodeId=8a441041500b9, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048290, encodeId=103b104829031, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
    2019-12-11 lovetcm

    与长寿有关

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1896589, encodeId=b5961896589ea, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Dec 19 07:36:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797874, encodeId=370b1e97874c6, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu May 28 07:36:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888096, encodeId=e5b7188809662, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Dec 21 23:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884043, encodeId=0cc21884043a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 24 00:36:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376866, encodeId=13173e686665, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK83Truj8NUgr5VYUNTe7l5Etf3AUFceibcFt9t5vmbcM5jv0udUW2sQlPFF7movto7JJ7GXMKNh5A/132, createdBy=8f6b5243615, createdName=dong8372, createdTime=Thu Dec 12 13:43:26 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376839, encodeId=01cc3e683915, content=与长寿有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 11 19:36:34 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041500, encodeId=8a441041500b9, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048290, encodeId=103b104829031, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
    2019-12-11 misszhang

    二甲双胍,神药!

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1896589, encodeId=b5961896589ea, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Thu Dec 19 07:36:00 CST 2019, time=2019-12-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1797874, encodeId=370b1e97874c6, content=<a href='/topic/show?id=27262399169' target=_blank style='color:#2F92EE;'>#二甲双胍能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23991, encryptionId=27262399169, topicName=二甲双胍能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=263b421, createdName=zhaozuguo, createdTime=Thu May 28 07:36:00 CST 2020, time=2020-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1888096, encodeId=e5b7188809662, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Sat Dec 21 23:36:00 CST 2019, time=2019-12-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1884043, encodeId=0cc21884043a4, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Sun May 24 00:36:00 CST 2020, time=2020-05-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376866, encodeId=13173e686665, content=很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTK83Truj8NUgr5VYUNTe7l5Etf3AUFceibcFt9t5vmbcM5jv0udUW2sQlPFF7movto7JJ7GXMKNh5A/132, createdBy=8f6b5243615, createdName=dong8372, createdTime=Thu Dec 12 13:43:26 CST 2019, time=2019-12-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=376839, encodeId=01cc3e683915, content=与长寿有关, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Wed Dec 11 19:36:34 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1041500, encodeId=8a441041500b9, content=二甲双胍,神药!, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048290, encodeId=103b104829031, content=什么时候有懒人用的减肥神药?, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Dec 11 18:36:00 CST 2019, time=2019-12-11, status=1, ipAttribution=)]
    2019-12-11 CHANGE

    什么时候有懒人用的减肥神药?

    0

相关资讯

J Endod:根管内二甲双胍通过抑制诱导型一氧化氮合酶表达以及单核细胞募集促进根尖周炎愈合

作者之前的研究显示,根管内二甲双胍能够部分通过调节成骨细胞凋亡改善根尖周炎的治疗效果。但二甲双胍在根尖周炎发展过程中对其他类型细胞的作用还需进一步研究。因此,这篇研究的目的是为了评估它对诱导型一氧化氮合酶(iNOS)表达以及单核细胞募集的作用是否有助于根尖周炎的愈合效果。

Cell Rep:揭开二甲双胍“神奇作用”的更多面纱...

众所周知,素有神药之称的二甲双胍是2型糖尿病的一线药物,它通过影响葡萄糖和脂质代谢而发挥作用,从而导致胰岛素敏感性增强。虽然近年来二甲双胍已经被充分研究,但对其控制血糖水平的分子基础研究人员仍知之甚少。因为到目前为止,对二甲双胍研究的特定生化途径数量有限。

Clin Cancer Res:靶向卵巢纤维化预防卵巢癌,神药二甲双胍从未让我们失望!

在刚刚举行的ESMO 2019 年会上,尼拉帕利作为维持卵巢癌的一线治疗再次取得了优异的成绩,临床试验中显示出了广谱的抗癌效果。与此同时,渥太华大学Barbara Vanderhyden博士的实验室对卵巢癌的研究也取得了新突破:卵巢纤维化作为卵巢癌的独立危险因素而存在,而神药二甲双胍竟可有效阻止这一过程,这无疑是卵巢癌研究的历史长河中浓墨重彩的一笔,卵巢癌患者的春天似乎要来了!

二甲双胍又“闪光”:可防腹主动脉瘤扩张

腹主动脉瘤就像体内埋伏的“炸弹”,扩张到一定程度就会发生破裂大出血。一项美国研究发现,得糖尿病的无症状腹主动脉瘤患者中,那些处方二甲双胍者的腹主动脉瘤就生长得慢。研究显示,在整个队列中,多元线性回归模型分析显示,腹主动脉瘤平均增长率为1.4 mm/年;多元混合效应模型分析显示,腹主动脉瘤平均增长率为1.3 mm/年。未校正前,二甲双胍组腹主动脉瘤平均增长率为1.2 mm/年,非二甲双胍组的腹主动脉

JCEM:二甲双胍与糖尿病患者阿尔茨海默氏病风险的关系

由此可见,在这个大型国家样本中,研究人员没有发现使用二甲双胍会增加患AD风险的证据。相反,长期和大剂量使用二甲双胍可降低老年糖尿病患者发生AD的风险。

JAMA Oncol:EGFR-TKIs治疗联合二甲双胍可明显改善晚期肺腺癌患者的PFS

盐酸二甲双胍是一种新型的抗癌药物。预临床和回顾性研究表明,它可以改善包括肺癌在内的多种肿瘤的预后。特别是关于二甲双胍与表皮生长因子受体(EGFR)-酪氨酸激酶抑制剂(TKIs)之间的协同作用的证据越来越多。Arrieta等人开展一非盲的随机化2期试验,评估采用EGFR-TKIs联合二甲双胍治疗 vs 单纯EGFR-TKIs治疗的晚期肺腺癌患者的无进展生存期(PFS)。招募年满18岁的组织学确诊的无

Baidu
map
Baidu
map
Baidu
map